Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Cyclophosphamide Based Regimens Compared to Plerixafor-Based Regimens for Stem Cell Mobilization in Patients with Multiple Myeloma Result in Higher CD34+ Cell Yield, Lower Cost and Similar Outcome Post Autologous Transplantation

Rima M Panchal, MD, Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Nino Aleksidze, MD, Andrew L. Pecora, MD, Andre Goy, MD, Maribel Pereiras, Pharm D, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 3283.

https://doi.org/10.1182/blood.V130.Suppl_1.3283.3283

Published: 2017

Journal Articles

Risk of Engraftment Syndrome after Autologous Stem Cell Transplantation for Multiple Myeloma Increases with Age and Lower Dose of CD34+ Cells, but Is Not Impacted By Immunomodulatory Chemotherapy

Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Nino Aleksidze, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 3284.

https://doi.org/10.1182/blood.V130.Suppl_1.3284.3284

Published: 2017

Journal Articles

Preliminary Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (I) and Nivolumab (N) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematologic Malignancies - Cpit-001 Trial

Blood (2017) 130 (Supplement 1): 340.

https://doi.org/10.1182/blood.V130.Suppl_1.340.340

Published: 2017

Journal Articles

Outcomes of Autologous Stem Cell Transplantation in Very Elderly Patients with Multiple Myeloma

Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, David H. Vesole, MD PhD, Scott D. Rowley, MD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Nino Aleksidze, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 2013.

https://doi.org/10.1182/blood.V130.Suppl_1.2013.2013

Published: 2017

Journal Articles

Patients Responding to Any First Line Therapy for Multiple Myeloma Should Proceed to Autologous Stem Cell Transplantation Instead of Receiving Second Line Therapy to Deepen Response

Nino Aleksidze, MD, Phyllis McKiernan, APN, MSN, David Siegel, MD PhD, Scott D. Rowley, MD, David H. Vesole, MD PhD, Tracy Andrews, PhD, Andrea Ortega, RN, Alan P Skarbnik, MD, Noa Biran, MD, Joshua R Richter, MD, Andrew L. Pecora, MD, Andre Goy, MD, Rima M Panchal, MD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 4538.

https://doi.org/10.1182/blood.V130.Suppl_1.4538.4538

Published: 2017

Journal Articles

Day 90 Post-Allogeneic Hematopoietic Cell Transplantation T Cell Receptor Diversity Level Correlates with Risk of Relapse in Patients with Multiple Myeloma

Robert Korngold, PhD, Kira Goldgirsh, MS, Themba Nyirenda, PhD, Phyllis McKiernan, APN, MSN, Ryan Emerson, PhD, Marissa Vignali, PhD, Julie Rubinstein, Harlan Robins, PhD, David Siegel, MD PhD, Michele L. Donato, MD

Blood (2017) 130 (Supplement 1): 4506.

https://doi.org/10.1182/blood.V130.Suppl_1.4506.4506

Published: 2017

Journal Articles

Long-Term Survival Is Demonstrated in Patients with Multiple Myeloma Treated with Allogeneic Hematopoietic Stem Cell Transplantation in Both the Consolidation and Salvage Settings

Phyllis McKiernan, APN, MSN, David S. Siegel, MD PhD, David H. Vesole, MD PhD, Tracy Andrews, MA, Scott D. Rowley, MD, Noa Biran, MD, Joshua R. Richter, MD, Andrew L. Pecora, MD, Alan P Skarbnik, MD, Andre Goy, MD, Michele L. Donato, MD

Blood (2016) 128 (22): 2302.

https://doi.org/10.1182/blood.V128.22.2302.2302

Published: 2016

Journal Articles

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation and Receive Salvage with Donor Lymphocyte Infusions (DLI)

Alan P Skarbnik, MD, Mary E DiLorenzo, APN, Tracy Andrews, MA, Phyllis McKiernan, APN, Scott D. Rowley, MD, David H. Vesole, MD PhD, Andre Goy, MD, Tatyana Feldman, MD, Lori A Leslie, MD, Lori A. Leslie, MD, Andrew L. Pecora, MD, Michele L. Donato, MD

Blood (2016) 128 (22): 5860.

https://doi.org/10.1182/blood.V128.22.5860.5860

Published: 2016

Journal Articles

High Rate of Engraftment Syndrome in Elderly Patients with Multiple Myeloma Receiving Autologous Peripheral Blood Stem Cell Transplantation

Phyllis McKiernan, APN, MSN, OCN, David Siegel, MD PhD, David H. Vesole, MD, Themba Nyirenda, PhD, Scott D. Rowley, MD FACP, Alan P Skarbnik, MD, Ann Ferolin-Ocot, RN, BSN, OCN, Daniel Kim, Neil Shah, MD, Michele L. Donato, MD

Blood (2015) 126 (23): 3175.

https://doi.org/10.1182/blood.V126.23.3175.3175

Published: 2015

Journal Articles

Haploidentical Allogeneic Transplantation As Salvage in Relapsed Multiple Myeloma

Phyllis McKiernan, APN, MSN, David H. Vesole, MD PhD, David S. Siegel, MD PhD, Scott D Rowley, MD FACP, Melissa F Baker, APN, Brenda Diaz, APN, Themba Nyirenda, PhD, Joshua R. Richter, MD, Pamela Sutherland, APN, Michele L. Donato, MD

Blood (2014) 124 (21): 5918.

https://doi.org/10.1182/blood.V124.21.5918.5918

Published: 2014

Journal Articles

Haploidentical Allogeneic Transplantation Provides Comparable Outcomes to HLA-Matched or Mismatched Unrelated Donor Grafts in Hematological Malignancies

Melissa F Baker, APN, Daniel Kim, Michele L Donato, MD FACP, Andrew L Pecora, MD FACP, David H. Vesole, MD PhD, Alan P Skarbnik, MD, Barbara Adler-Brecher, Michele Boonstra, APN, Brenda Diaz, APN, Phyllis McKiernan, APN, Pamela Sutherland, APN, Scott D Rowley, MD FACP

Blood (2014) 124 (21): 1226.

https://doi.org/10.1182/blood.V124.21.1226.1226

Published: 2014

Journal Articles

Long-Term Follow-up of Patients With Multiple Myeloma Who Received Allogeneic Hematopoietic Stem Cell Transplantation

Michele L. Donato, MD, David S Siegel, MD, PhD., David H. Vesole, MD, PhD, Phyllis McKiernan, APN, Themba Nyirenda, Ph D, Melissa Baker, APN, Anthony Mato, Joshua R. Richter, MD, Andrew L Pecora, MD, Scott D Rowley, MD

Blood (2013) 122 (21): 2154.

https://doi.org/10.1182/blood.V122.21.2154.2154

Published: 2013

Journal Articles

Donor CD3 Chimerism After Allogeneic Transplantation Predicts Probability Of Relapse For Patients Treated For Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and Non-Hodkgin's Lymphoma (NHL)

George Nahas, DO, Arpita P Gandhi, MD, Michele L. Donato, MD, Themba Nyirenda, PhD, David H. Vesole, MD, PhD, Andrew L Pecora, Stuart Goldberg, MD, Andre Goy, MD, Tatyana Feldman, MD, Anthony R. Mato, MD, Pritish K. Bhattacharyya, MD, Melissa Baker, APN, Phyllis McKiernan, APN, Brenda Diaz, APN, Scott D Rowley, MD, FACP

Blood (2013) 122 (21): 4545.

https://doi.org/10.1182/blood.V122.21.4545.4545

Published: 2013

Journal Articles

Decitabine Plus Mini Fludarabine and Busulfan Yields Durable Engraftment with Low Relapse Rates in Elderly or Medically Infirm Patients with Myeloid Malignancies

Melissa F Baker, APN, Scott D Rowley, MD, Stuart L. Goldberg, MD, Anthony R Mato, MD, Andrew L Pecora, MD, David H. Vesole, MD, PhD, Phyllis McKiernan, APN, Andre Goy, MD, Michele L. Donato, MD

Blood (2012) 120 (21): 1936.

https://doi.org/10.1182/blood.V120.21.1936.1936

Published: 2012

Journal Articles

Unrelated Donor Hematopoietic Stem Cell Transplantation for the Treatment of Advanced Multiple Myeloma: The John Theurer Cancer Center Experience,

Michele L. Donato, MD, David H. Vesole, MD, PhD, David S. Siegel, MD, PhD, Barbara Adler-Brecher, Eiswarya Chichili, MD, Andrew L Pecora, MD, Phyllis McKiernan, APN, Melissa Baker, APN, Themba Nyirenda, PhD, Elizabeth Bilotti, MSN, RN, Andre Goy, MD, Scott D Rowley, MD

Blood (2011) 118 (21): 4162.

https://doi.org/10.1182/blood.V118.21.4162.4162

Published: 2011

NARROW

Cyclophosphamide Based Regimens Compared to Plerixafor-Based Regimens for Stem Cell Mobilization in Patients with Multiple Myeloma Result in Higher CD34+ Cell Yield, Lower Cost and Similar Outcome Post Autologous Transplantation

Risk of Engraftment Syndrome after Autologous Stem Cell Transplantation for Multiple Myeloma Increases with Age and Lower Dose of CD34+ Cells, but Is Not Impacted By Immunomodulatory Chemotherapy

Preliminary Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (I) and Nivolumab (N) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematologic Malignancies - Cpit-001 Trial

Outcomes of Autologous Stem Cell Transplantation in Very Elderly Patients with Multiple Myeloma

Patients Responding to Any First Line Therapy for Multiple Myeloma Should Proceed to Autologous Stem Cell Transplantation Instead of Receiving Second Line Therapy to Deepen Response

Day 90 Post-Allogeneic Hematopoietic Cell Transplantation T Cell Receptor Diversity Level Correlates with Risk of Relapse in Patients with Multiple Myeloma

Long-Term Survival Is Demonstrated in Patients with Multiple Myeloma Treated with Allogeneic Hematopoietic Stem Cell Transplantation in Both the Consolidation and Salvage Settings

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation and Receive Salvage with Donor Lymphocyte Infusions (DLI)

High Rate of Engraftment Syndrome in Elderly Patients with Multiple Myeloma Receiving Autologous Peripheral Blood Stem Cell Transplantation

Haploidentical Allogeneic Transplantation As Salvage in Relapsed Multiple Myeloma

Haploidentical Allogeneic Transplantation Provides Comparable Outcomes to HLA-Matched or Mismatched Unrelated Donor Grafts in Hematological Malignancies

Long-Term Follow-up of Patients With Multiple Myeloma Who Received Allogeneic Hematopoietic Stem Cell Transplantation

Donor CD3 Chimerism After Allogeneic Transplantation Predicts Probability Of Relapse For Patients Treated For Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and Non-Hodkgin's Lymphoma (NHL)

Decitabine Plus Mini Fludarabine and Busulfan Yields Durable Engraftment with Low Relapse Rates in Elderly or Medically Infirm Patients with Myeloid Malignancies

Unrelated Donor Hematopoietic Stem Cell Transplantation for the Treatment of Advanced Multiple Myeloma: The John Theurer Cancer Center Experience,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only